Welcome to our dedicated page for ENCISION news (Ticker: ECIA), a resource for investors and traders seeking the latest updates and insights on ENCISION stock.
Encision Inc. (ECIA) is a Boulder, Colorado-based medical device company specializing in the development and marketing of patented Active Electrode Monitoring (AEM®) Technology. The core of Encision’s mission is to enhance patient safety by preventing dangerous stray energy burns during minimally invasive surgeries. This is achieved through their innovative AEM® laparoscopic instruments and the AEM EndoShield™ burn protection system.
Every ninety minutes in the United States, a patient suffers from a stray energy burn during laparoscopic procedures, which are entirely preventable. Encision’s state-of-the-art AEM® monopolar energy technology combats these burns, which are typically caused by insulation failure and capacitive coupling. By eliminating such risks, Encision’s technology actively saves lives and improves surgical outcomes.
In recent achievements, Encision reported a quarterly net revenue of $1.81 million for the fiscal fourth quarter ending March 31, 2023, with a net loss significantly reduced to $93 thousand compared to previous periods. The gross margin on net revenue increased to 56% due to enhanced operating efficiencies and higher selling prices.
Encision continues to navigate the challenges posed by market fluctuations and the aftermath of the COVID-19 pandemic. Despite these adversities, the company has strengthened its sales channels and initiated new product developments. Collaborative efforts are also underway, promising beneficial outcomes for both Encision and its partners in the upcoming fiscal year.
Encision’s product portfolio features high-performance surgical instruments tailored for a wide array of minimally invasive procedures. These instruments incorporate AEM technology, advancing patient safety, surgical performance, and delivering significant value to hospitals. For more details on their products, please visit their website at www.encision.com.
Latest News: Encision's financial results for the fiscal 2024 first quarter, ending June 30, 2023, indicate a total net revenue of $1.65 million and a net loss of $140 thousand. The company continues to show resilience and innovation amidst market challenges, evidenced by their efforts to revitalize service revenue streams and maintain high gross margins.
Encision Inc. (OTC PINK:ECIA) reported financial results for Q2 FY2025 ending September 30, 2024. Total net revenue was $1.75 million, down from $1.83 million in Q2 FY2024, with a quarterly net loss of $170,000 ($(0.01) per share). Product net revenue decreased to $1.65 million from $1.75 million year-over-year, while service revenue increased to $101,000. The company maintained a 47% gross margin on product revenue. For the six-month period, total revenue was $3.39 million with a net loss of $148,000. Performance was impacted by reduced surgical procedures due to hurricanes in the southeast and saline availability issues. The company plans to launch a new ENT market product in early FY2026.
Encision Inc. (OTC PINK:ECIA), a medical device company specializing in Active Electrode Monitoring (AEM) Technology, has signed a Master Services Agreement with Vicarious Surgical Inc. The agreement, effective July 8, 2024, involves Encision providing design services for elements of Vicarious' robotic surgical system.
Gregory J. Trudel, President and CEO of Encision, expressed excitement about the collaboration, highlighting the opportunity to bring best-in-class technology to surgical robotics and contribute to patient safety and clinical performance. Encision, based in Boulder, Colorado, focuses on developing surgical instrumentation that enhances patient safety and surgical performance across various minimally invasive procedures.
Encision Inc. (OTC PINK:ECIA), a medical device company specializing in Active Electrode Monitoring (AEM) Technology, reported financial results for its fiscal 2025 first quarter ended June 30, 2024. The company achieved:
- Total net revenue of $1.63 million
- Quarterly net income of $22,000 ($0.00 per diluted share)
- Product net revenue of $1.59 million
- Service net revenue of $39,000
- Gross margin on product net revenue increased to 58% from 52% in the previous year
The improved performance is attributed to higher operating efficiencies and increased selling prices. CEO Gregory Trudel highlighted the company's progress in sales channel investment and technology development, as well as efforts to create new service revenue streams.
Encision Inc. (OTCPK:ECIA), a medical device company specializing in Active Electrode Monitoring (AEM) Technology, reported its fiscal 2024 fourth quarter and full-year results. Key points:
- Q4 net revenue: $1.53 million, down from $1.81 million year-over-year
- Q4 net loss: $409,000 or $(0.03) per diluted share
- Full-year net revenue: $6.59 million, down from $7.35 million in fiscal 2023
- Full-year net loss: $692,000 or $(0.06) per diluted share
- Gross margin decreased to 42% in Q4 and 48% for the full year
The company faced challenges due to COVID-19 impacts and market changes but remains optimistic about fiscal 2025 with a strengthening sales channel and new product introduction.
Encision Inc. (OTC PINK:ECIA) has signed a Supplier Agreement with Human Xtensions, marking a strategic partnership aimed at enhancing robotic surgery performance. Encision will provide manufacturing services, including procurement, assembly, and testing of products tailored to Human X's specifications. This collaboration aims to elevate clinical performance through Encision's innovative Active Electrode Monitoring (AEM) Technology and advanced surgical instruments. Gregory J. Trudel, CEO, expressed enthusiasm for the partnership's potential to set new standards in surgical precision. However, the company acknowledges inherent risks in product development and market acceptance.
Encision Inc. (OTC PINK:ECIA) announced its fiscal Q3 2023 results, reporting net revenue of $1.68 million and a net loss of $216 thousand, or $(0.02) per diluted share. This represents a revenue decline from $1.94 million and a net loss of $16 thousand in Q3 2022. For nine months, the company achieved net revenue of $5.54 million with a net loss of $231 thousand, compared to $6.07 million and income of $337 thousand in the same period last year. Despite these challenges, gross margins improved to 54% due to better operational efficiency. The CEO attributed the revenue drop to decreased surgical procedures, COVID impacts, and affordability issues among patients.
FAQ
What is the current stock price of ENCISION (ECIA)?
What is the market cap of ENCISION (ECIA)?
What does Encision Inc. specialize in?
What are Encision’s primary products?
How does Encision’s AEM® technology improve patient safety?
What were Encision's financial results for the fiscal 2023 fourth quarter?
How did Encision perform in the first quarter of fiscal 2024?
What challenges has Encision faced recently?
Where is Encision Inc. headquartered?
How can I get more information about Encision’s products?
What is the significance of Encision’s AEM® technology?
How has Encision adapted to market changes?
